X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Misses Estimates By $0.03 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) announced its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03), Zacks reports.

X4 Pharmaceuticals Trading Down 4.0 %

XFOR stock opened at $0.30 on Tuesday. The company has a market cap of $51.23 million, a price-to-earnings ratio of -3.28 and a beta of 0.39. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The business has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.53.

Insiders Place Their Bets

In other news, CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 202,663 shares of company stock worth $91,198 over the last ninety days. 1.62% of the stock is owned by company insiders.

Institutional Trading of X4 Pharmaceuticals

An institutional investor recently raised its position in X4 Pharmaceuticals stock. Bank of America Corp DE raised its position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,502 shares of the company’s stock after purchasing an additional 22,485 shares during the quarter. Bank of America Corp DE owned about 0.08% of X4 Pharmaceuticals worth $98,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.